Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVO-001
- Development stage
- Preclinical
- Lead developer
- Evozyne
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Parenteral
01
Overview
EVO-001 is an investigational protein therapeutic being developed by Evozyne for the treatment of rare autoimmune diseases. The drug is designed using Evozyne's proprietary protein engineering platform, which leverages generative AI and evolutionary algorithms to create novel proteins with optimized functional properties. As of August 2026, EVO-001 is in the IND-enabling phase of development, representing a lead internal program for the company. While specific molecular target and modality details have not been publicly disclosed, the program is aimed at addressing high unmet needs in the autoimmune space through advanced protein design.
Beyond the preview
Go deeper on EVO-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVO-001.